(Q38082233)

28 August 2017

Active immunotherapy for chronic diseases (English)

1 reference

28 August 2017

1 reference

1

Martin F Bachmann

1 reference

28 August 2017

Piers Whitehead

2

1 reference

PubMed ID

23415932

28 August 2017

language of work or name

English

0 references

publication date

14 February 2013

1 reference

28 August 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

28 August 2017

31

1 reference

28 August 2017

14

1 reference

28 August 2017

1777-1784

1 reference

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Long-term durability of response to adalimumab in Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatolo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Maintenance therapy with certolizumab pegol for Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Overview of biologic therapy for Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Aggregation, stability, and formulation of human antibody therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Adherence with statin therapy in elderly patients with and without acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Production of recombinant HIV-1 nef protein using different expression host systems: a techno-economical comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Industrialization of mAb production technology: the bioprocessing industry at a crossroads

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

The economic impact of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

7 January 2021

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

Therapeutic vaccination for chronic diseases: a new class of drugs in sight

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

A vaccine that prevents pregnancy in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.001

10.1016/J.VACCINE.2013.02.001

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23415932